340B Drug Pricing Program

The AHA July 14 urged the Health Resources and Services Administration to revise its estimate of the administrative burden associated with the agency’s proposed 340B rebate model pilot program, saying the agency’s projection of five hours of work per week significantly understates the real-…
The AHA today filed a friend-of-the-court brief supporting the Department of Health and Human Services’ motion to dismiss AbbVie’s lawsuit challenging the agency’s longstanding definition of “patient” under the 340B Drug Pricing Program.
AHA responds to Information Collection Request about the Health Resources and Services Administration’s proposed 340B Rebate Model Program.
The AHA, America’s Essential Hospitals, the Children’s Hospital Association, the Association of American Medical Colleges, and the American Society of Health-System Pharmacists today filed a friend-of-the-court brief supporting the Department of Health and Human Services’ motion to dismiss AbbVie’s…
The Health Resources and Services Administration announced that 340B covered entities purchased $100 billion in outpatient drugs under the federal 340B Drug Pricing Program in calendar year 2025.
The AHA shares the goal of making healthcare more affordable and accessible. We recently released actionable, achievable strategies that will help drive care transformation and make care more affordable.
The AHA today released legislative advisories on a 340B bill introduced by a bipartisan House working group and a legislative discussion draft introduced in the Senate.
On June 29, Sen. Bill Cassidy, R-La., unveiled a legislative discussion draft titled the 340B Drug Pricing Integrity and Affordability for Patients Act.
Reps. Scott Peters, D-Calif., and John Joyce, R-Pa., introduced the Strengthening the Exercise of Controls and Upgrading Requirements for Efficiency in 340B Act, or SECURE 340B Act.
If you haven’t done so yet, please register for an AHA 340B Advocacy Alliance call on July 8 at 3 p.m. ET to hear the latest updates on the 340B Drug Pricing Program.